Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Scancell Receives GTAC, MHRA Approval For SCIB1 Phase I Trial
Scancell said that SCIB1 is a new DNA ImmunoBody vaccine being developed using its patented ImmunoBody technology for the treatment of melanoma. In addition, Scancell’s US partner Ichor
Scancell said that SCIB1 is a new DNA ImmunoBody vaccine being developed using its patented ImmunoBody technology for the treatment of melanoma. In addition, Scancell’s US partner Ichor
Abbott has claimed that the center is the largest nutrition R&D facility outside of the US, and Singapore’s first nutrition R&D site creating science-based nutritional products for infants,
EndoCeutics will be responsible for conducting the Phase III studies for Vaginorm. Thereafter, Bayer will be responsible for the registration and commercialization of Vaginorm. Under the terms of
PerkinElmer claimed that the Prenatal BoBs assay is the first IVD product from the BACs-on-Beads multiplexed bead-based technology product family. The assay is a novel solution for IVD
IDT said that while traditional probes have 20-30 bases between the dye and quencher, the new proprietary probe design positions an internal Zen quencher only 9 bases from
Micronics said that the test is not for use for blood bank processing of blood products but for determining RHD status for the purpose of administration of Rh
Reportedly, Illumina had introduced the BeadXpress system in 2007 with Research Use Only kits for custom genotyping, gene expression, methylation and protein analysis. Since then it has been
Under the agreement, Actavis will develop, obtain US FDA approval and supply the products, which Sagent will market in the US. Jeffrey Yordon, CEO, founder and chairman of
The change is to include supplemental data demonstrating significant improvement in attention in adults with ADHD across all six assessments conducted at two, four, eight, 10, 12 and
As a result of the acquisition, DSM Biologics will gain all rights for the commercialisation of the Rhobust technology in various fields, including the pharma industry. The Rhobust